SciClone Pharmaceuticals (Holdings) Limited
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From SciClone Pharmaceuticals (Holdings) Limited
The UK biotech looks to have reached the end of the road, despite some encouraging signs from its microbiome-based pipeline.
F-star's novel bispecific technology attracts Sino Biopharma-affiliated acquisition, Shionogi agreement with GARDP brings antibiotic cefiderocol to 135 countries, deal with WinHealth covering Greater China expands Quoin’s licensing of Netherton syndrome candidate to 60 nations, Kyorin and CellGenTech team up in Fabry disease.
National Resilience, Parker Institute team to incubate cancer startups. Metropolitan AntiViral Drug Accelerator will focus on eight molecular features of SARS-CoV-2 to create novel oral antivirals.
Private Company Edition: The global accelerator has new commitments from HHS and the Wellcome Trust. Also, Apollo buys into Sofinnova Partners with an up to €1bn investment, Castle Creek raised $124.6m in private funding this year in lieu of an IPO and Remix closed a $70m series B round.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- NovaMed Pharmaceuticals Inc.
- SciClone Pharmaceuticals Inc.